Clinical Trial Update: Evaluating Safety & Efficacy of Apremilast in the Treatment of Cutaneous Disease in Patients With Recalcitrant Dermatomyositis [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating apremilast for safety and efficacy in adult dermatomyositis has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dermatomyositis

Drugs mentioned

• Apremilast (apremilast)

Snippet

Sponsor: Tulane University | Conditions: Dermatomyositis, Adult Type | Phase 2 | Status: COMPLETED | Results posted: 2023-03-03